Keros Therapeutics (KROS) Cash from Financing Activities (2019 - 2025)

Keros Therapeutics (KROS) has 7 years of Cash from Financing Activities data on file, last reported at -$378.6 million in Q4 2025.

• Quarterly Cash from Financing Activities fell 601.21% year-over-year to -$378.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$378.5 million (down 196.59% YoY) and the FY2025 annual result came in at -$378.5 million, down 196.59% from the prior year.
• Cash from Financing Activities retreated to -$378.6 million in Q4 2025, from $140000.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $156.8 million in Q1 2024 to a low of -$378.6 million in Q4 2025.
• A 5-year average of $17.1 million and a median of $2.6 million in 2023 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities jumped 138708.57% — and 2025, when it plunged 601.21%.
• Tracing KROS's Cash from Financing Activities over 5 years: stood at $28.4 million in 2021, then soared by 116.13% to $61.4 million in 2022, then gained by 12.76% to $69.3 million in 2023, then gained by 9.08% to $75.5 million in 2024, then sank by 601.21% to -$378.6 million in 2025.
• The last three Cash from Financing Activities figures came in at -$378.6 million (Q4 2025), $140000.0 (Q3 2025), and $17000.0 (Q2 2025), per Business Quant data.